Abciximab in carotid stenting for postsurgical carotid restenosis: Intermediate results

Journal of Endovascular Therapy

Volumn 7, Issue 4, 2000, Pages 263-272

  Schneiderman, Jacob ^a,e   Morag, Benyamina ^b   Gerniak, Alexander ^b   Rimon, Uri ^b   Varon, David ^c   Seligsohn, Uri ^c   Shotan, Avraham ^d   Adar, Raphael ^a  

^a Department of Vascular Surgery   (Israel)

^b Department of Radiology ^*  (Israel)

^c The Amalia Biron Research Institute of Thrombosis and Hemostasis   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e SHEBA MEDICAL CENTER   (Israel)

Author keywords

Angioplasty; Intimal hyperplasia; Platelet aggregation inhibitors; ReoPro

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INTERNAL CAROTID ARTERY OCCLUSION; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RESTENOSIS; STENT; TREATMENT OUTCOME;

EID: 0033904654     PISSN: 15266028     EISSN: None     Source Type: Journal    
DOI: 10.1177/152660280000700402     Document Type: Article

References (40)

1. Gagne PJ, Riles TS, Jacobowitz GR, et al. Long-term follow-up of patients undergoing reoperation for recurrent carotid artery disease. J Vasc Surg. 1993;18:991-1001.
2. Carballo RE, Towne JB, Seabrook GR, et al. An outcome analysis of carotid endarterectomy: the incidence and natural history of recurrent stenosis. J Vasc Surg. 1996;23:749-754.
3. Badimon L, Badimon JJ, Turitto VT, et al. Platelet thrombus formation on collagen type 1. A model of deep vessel wall injury. Influence of rheology, von Willebrand factor, and blood coagulation. Circulation. 1988;78:1431-1442.
4. Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1562-1569.
5. O'Donnell TF Jr., Rodriguez AA, Fortunato JE, et al. Management of recurrent carotid stenosis: should asymptomatic lesions be treated surgically? J Vasc Surg. 1996;24:207-212.
6. Mansour A, Kang SS, Baker WH, et al. Carotid endarterectomy for recurrent stenosis. J Vasc Surg. 1997;25:877-883.
7. Piepgras DG, Sundt TM, Marsh WR, et al. Recurrent carotid stenosis: results and complications in 57 operations. Ann Surg. 1986;203: 205-213.
8. Bartlett FF, Rapp JH, Goldstone J, et al. Recurrent carotid stenosis: operative strategy and late results. J Vasc Surg. 1987;5:452-456.
9. Rockman CB, Riles TS, Landis R, et al. Redo carotid surgery: an analysis of materials and configurations used in carotid reoperations and their influence on perioperative stroke and subsequent recurrent stenosis. J Vasc Surg. 1999;29:72-81.
10. Hill BB, Olcott C, Dalman RL, et al. Reoperation for carotid stenosis is as safe as primary carotid endarterectomy. J Vasc Surg. 1999;30:26-35.
11. Naylor AR, Bolia A, Abbott RJ, et al. Randomized study of carotid angioplasty and stenting versus carotid endarterectomy: a stopped trial. J Vasc Surg. 1998;28:326-334.
12. Bergeron P, Chambran P, Benichou H, et al. Recurrent carotid disease: will stents be an alternative to surgery? J Endovasc Surg. 1996;3:76-79.
13. Diethrich EB, Ndiaye M, Reid BD. Stenting in the carotid artery: initial experience in 110 patients. J Endovasc Surg. 1996;3:42-62.
14. Yadav JS, Roubin GS, lyer S, et al. Elective stenting of the extracranial carotid arteries. Circulation. 1997;95:376-381.
15. Dangas G, Laird JR, Satler LF, et al. Is carotid stenting the preferred treatment in high-risk surgical carotid endarterectomy patients? J Am Coll Cardiol. 1999;33(suppl A):64A.
16. Henry M, Amor M, Henry I, et al. Carotid stenting with cerebral protection: first clinical experience using the PercuSurge GuardWire system. J Endovasc Surg. 1999;6:321-331.
17. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
18. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
19. Topol EJ, Califf RM, Weisman HF, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
20. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA. 1997;278:479-484.
21. Lincoff AM, Popma JJ, Ellis SG, et al. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol. 1992;19:926-935.
22. White GH, Liew SC, Waugh RC, et al. Early outcome and intermediate follow-up of vascular stents in femoral and popliteal arteries without long-term anticoagulation. J Vasc Surg. 1995; 21:270-279.
23. Toschi V, Gallo R, Lenino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594-599.
24. Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA. 1992;89: 6998-7002.
25. Coller BS, Folts JD, Scudder LE, et al. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood. 1986;68: 783-786.
26. Bates ER, McGillem MJ, Mickelson JK, et al. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation. 1991;84:2463-2464.
27. The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation. 1999; 100:799-806.
28. Jawien A, Bowen PDF, Lindner V, et al. Platelet-derived growth factor promotes smooth muscle migration and intimai thickening in a rat model of balloon angioplasty. J Clin Invest. 1992;89:507-511.
29. Majesky MW, Lindner V, Twardzik DR, et al. Production of transforming growth factor β1 during repair of arterial injury. J Clin Invest. 1991 ;88:904-910.
30. Reidy MA, Fingerle J, Lindner V. Factors controlling the development of arterial lesions after injury. Circulation. 1992;86(suppl):III-43-III-46.
31. Lefkovitz J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
32. 3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor 1. Proc Natl Acad Sci USA. 1996;93:2482-2487.
33. Speir E, Modali R, Huang ES, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994; 265:391-394.
34. 3 during angiogenesis. J Clin Invest. 1996;98:426-433.
35. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by mouse/human chime-ric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest. 1996;98:863-874.
36. Dangas G, Badimon JJ, Coller BS, et al. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition. Implications for the potential anticoagulant effect of abciximab. Arterioscl Thromb Vasc Biol. 1998;18:1342-1349.
37. Ohki T, Marin ML, Lyon RT, et al. Ex vivo human carotid artery bifurcation stenting: correlation of lesion characteristics with embolic potential. J Vasc Surg. 1998;27:463-471.
38. Von-Ingersleben G, Schmiedl UP, Hatsukami TS, et al. Characterization of atherosclerotic plaques at the carotid bifurcation: correlation of high-resolution MR imaging with histologic analysis. Preliminary study. Radiographics. 1997;17:1417-1423
39. Zimmermann-Paul GG, Quick HH, Vogt P, et al. High resolution intravascular magnetic resonance imaging monitoring of plaque formation in heritable hyperlipidemic rabbits. Circulation. 1999;99:1054-1061.
40. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials in perspective. Am J Cardiol. 1996;78(suppl 3A):35-40.